DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT
FOR A VETERINARY MEDICINAL PRODUCT

ANAESTAMINE 100 MG/ML SOLUTION FOR INJECTION

Date: 09/09/2014
**PRODUCT SUMMARY**

<table>
<thead>
<tr>
<th>EU Procedure number</th>
<th>FR/V/0262/001/DC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name, strength and pharmaceutical form</td>
<td>ANAESTAMINE 100 MG/ML SOLUTION FOR INJECTION</td>
</tr>
<tr>
<td>Applicant</td>
<td>LE VET BEHEER BV WILGENWEG 7, 3421 TV OUDEWATER THE NETHERLANDS</td>
</tr>
<tr>
<td>Active substance(s)</td>
<td>Ketamine hydrochloride</td>
</tr>
<tr>
<td>ATC Vetcode</td>
<td>QN01AX03</td>
</tr>
<tr>
<td>Target species</td>
<td>Dogs, cats, cattle, sheep, goats, horses, pigs, guinea pigs, hamsters, rabbits, rats, mice.</td>
</tr>
<tr>
<td>Indication for use</td>
<td>The product may be used in combination with a sedative for: - Immobilisation - Sedation - General anaesthesia</td>
</tr>
</tbody>
</table>

**MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the website [http://www.anmv.anses.fr/](http://www.anmv.anses.fr/)
PUBLIC ASSESSMENT REPORT

Legal basis of original application | Generic application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
---|---
Date of completion of the original decentralised procedure | 18/06/2014
Concerned Member States for original procedure | AT; BE; CZ; DK; EE; EL; ES; FI; HU; IE; IS; IT; LT; LU; LV; NL; NO; PL; PT; RO; SE; SK; UK

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC. The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy of the product was demonstrated according to the claims made in the SPC. The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Composition

The product contains 100 mg/ml ketamine (as hydrochloride) as active substance, and excipients chlorocresol, sodium hydroxide and water for injections. The container is a glass vials closed with a bromobutyl rubber stopper. The particulars of the container and controls performed are provided and conform to the regulation. The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The product is manufactured in accordance with the European Pharmacopoeia and relevant European guidelines.
C. **Control of Starting Materials**

The active substance is ketamine, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice. The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

D. **Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies**

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

E. **Control on intermediate products**

Not applicable.

F. **Control Tests on the Finished Product**

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

G. **Stability**

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions. Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions. An in-use shelf-life as detailed on the SPC has been supported by appropriate data.

H. **Genetically Modified Organisms**

Not applicable.

J. **Other Information**

Not applicable.
III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

As this is a generic application submitted according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the reference product can be assumed because of the nature of the product, results of pharmacological studies are not required.

The pharmacological aspects of this product are identical to the reference product.

Toxicological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Ecotoxicity

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment was required.

III.B Residues documentation

Residue Studies

No residue depletion studies were conducted.

MRLs

a. active substances

The active substance, ketamine, is included in table 1 of the MRL regulation 37/2010, without ADI, as follows:
b. excipients

The MRL status of excipients of the tested product is indicated in the following table:

<table>
<thead>
<tr>
<th>Excipient</th>
<th>MRL status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorocresol</td>
<td>No MRL required</td>
</tr>
<tr>
<td>Sodium hydroxyde</td>
<td>No MRL required</td>
</tr>
<tr>
<td>Purified water</td>
<td>Out of scope list</td>
</tr>
</tbody>
</table>

Withdrawal Periods

The same withdrawal periods as the European reference product have been applied:

Cattle, sheep, goats and horses:
Meat and offal: 1 day.
Milk: zero days.

Pigs:
Meat and offal: 1 day.

IV. CLINICAL ASSESSMENT (EFFICACY)

IV.A Pre-Clinical Studies

Tolerance in the Target Species of Animals

The applicant has not provided tolerance study which is acceptable because:
- the tested product and the reference product are bioequivalent,
- the excipients of the tested product are deemed unproblematic as regards tolerance.

IV.B Clinical Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

V. OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.